

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 January 2023 (26.01.2023)



(10) International Publication Number
WO 2023/002407 A2

(51) International Patent Classification:
A61K 31/53 (2006.01)

(21) International Application Number:
PCT/IB2022/056709

(22) International Filing Date:
20 July 2022 (20.07.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/223,711 20 July 2021 (20.07.2021) US

(71) Applicants: **MINERALYS THERAPEUTICS, INC.** [US/US]; 150 N. Radnor Chester Rd, Suite F200, Radnor, Pennsylvania 19087 (US). **MITSUBISHI TANABE PHARMA CORPORATION** [JP/JP]; 2-10 Dosho-machi, 3-chome, Chuo-ku, Osaka, Hokkaido 541-8505 (JP).

(72) Inventors: **MCKEAN, Robert**; c/o Mineralys Therapeutics, Inc., 150 N. Radnor Chester Rd, Suite F200, Radnor, Pennsylvania 19087 (US). **OHASHI, Yoshinori**; c/o Mitsubishi Tanabe Corporation, 2-10 Dosho-machi, 3-chome, Chuo-ku, Osaka, Hokkaido 541-8505 (JP). **OZAKI, Fuminori**; c/o Mitsubishi Tanabe Pharma Corporation, 2-10 Dosho-machi, 3-chome, Chuo-ku, Osaka, Hokkaido 541-8505 (JP). **OHSHIMA, Hiroki**; c/o Mitsubishi Tanabe Pharma Corporation, 2-10 Dosho-machi, 3-chome, Chuo-ku, Osaka, Hokkaido 541-8505 (JP). **NAGATA, Hiroomi**; c/o Mitsubishi Tanabe Pharma Corporation, 2-10 Dosho-machi, 3-chome, Chuo-ku, Osaka, Hokkaido 541-8505 (JP).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,


TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: SOLUBLE PHARMACEUTICAL COMPOSITIONS COMPRISING SALTS OF DISUBSTITUTED 1, 2, 4-TRIAZINE COMPOUND



3-[4-[[trans-4-(acetoamino)cyclohexyl]carbamoylmethyl]piperazin-1-yl]-5-(p-tolyl)-1,2,4-triazine

(57) Abstract: Disclosed are pharmaceutical compositions comprising a salt of a compound having the formula (I): Formula (I) and one or more excipients, wherein the pharmaceutical composition avoids inducing disproportionation of the salt of the compound.



WO 2023/002407 A2